HIV-specific T-cell induction

Details HIV-specific T-cell induction HIV-specific T-cell induction

2007-12-11

2007-12-11

Campell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S185100, C424S186100, C424S187100, C530S324000, C530S325000, C530S826000

Reexamination Certificate

active

10673671

ABSTRACT:
This invention discloses diagnostic, preventative, and treatment therapies of AIDS involving determining whether a subject exhibits an HLA-Cw7-restricted CTL response. Some methods are directed to the use of HLA-Cw7 as a genetic marker for long-term non-progression and amenability to treatment therapies. Diagnostic methods include a method for predicting long term non-progression in an HIV-infected subject. Preventative and treatment methods encompass determining whether a subject exhibits or can exhibit an HLA-Cw7-restricted CTL response. They also encompass ways of eliciting such a response, if necessary. Furthermore, some of the methods involve administering one or more HIV polypeptides or peptides, or polynucleotides encoding them, as a treatment therapy to prevent the development of AIDS.

REFERENCES:
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3949064 (1976-04-01), Bornstein et al.
patent: 4174384 (1979-11-01), Ullman et al.
patent: 4367110 (1983-01-01), Yoshikawa
patent: 4452901 (1984-06-01), Gordon et al.
patent: 4554101 (1985-11-01), Hopp
patent: 4578770 (1986-03-01), Mitani
patent: 4596792 (1986-06-01), Vyas
patent: 4599230 (1986-07-01), Milich et al.
patent: 4601903 (1986-07-01), Frasch
patent: 4608251 (1986-08-01), Mia
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4690915 (1987-09-01), Rosenburg
patent: 4797368 (1989-01-01), Carter et al.
patent: 4800159 (1989-01-01), Mullis et al.
patent: 4883750 (1989-11-01), Whiteley et al.
patent: 4942628 (1990-07-01), Rosen et al.
patent: 5028592 (1991-07-01), Lipton
patent: 5128319 (1992-07-01), Arlinghaus
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5142025 (1992-08-01), Putney et al.
patent: 5199942 (1993-04-01), Gillis
patent: 5221605 (1993-06-01), Bard et al.
patent: 5238808 (1993-08-01), Bard et al.
patent: 5279721 (1994-01-01), Schmid
patent: 5310687 (1994-05-01), Bard et al.
patent: 5620896 (1997-04-01), Herrmann et al.
patent: 5780036 (1998-07-01), Chisari
patent: 5958895 (1999-09-01), Pachuk et al.
patent: 6210873 (2001-04-01), Sastry et al.
patent: 6271198 (2001-08-01), Braisted et al.
patent: 0 267 802 (1988-05-01), None
patent: 0 273 716 (1988-07-01), None
patent: 0 284 587 (1988-09-01), None
patent: 320308 (1989-06-01), None
patent: 329822 (1989-08-01), None
patent: 2202328 (1988-09-01), None
patent: WO 88/10315 (1988-12-01), None
patent: WO 89/03844 (1989-05-01), None
patent: WO 89/06700 (1989-07-01), None
patent: WO 89/07112 (1989-08-01), None
patent: WO 90/07641 (1990-07-01), None
patent: WO 93/10816 (1993-06-01), None
patent: WO 93/19775 (1993-10-01), None
patent: WO 96/33734 (1996-10-01), None
Agren et al., “Genetically engineered nontoxic vaccine adjuvent that combines B cell targeting with immunomodulation by cholera toxin A1 subunit,”J. Immunol. 158:3936-3946, 1997.
Aichele et al., “Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide,”J. Exp. Med., 171:1815-1820, 1990.
Altman et al., “Phenotypic analysis of antigen-specific T lymphocytes,”Science, 274:94-96, 1996.
An and Whitton, “A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Thepitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen,”J. Virol., 71(3):2292-2302, 1997.
Barry et al., “Protection against mycoplasma infection using expression-library immunization,”Nature, 377:632-635, 1995.
Berzofsky, “Development of artificial vaccines against HIV using defined epitopes,”FASEB J., 5:2412-2418, 1991.
Bevan, “Stimulating killer cells,”Nature, 342:478-479, 1989.
Bogedain et al., “Specific cytotoxic T lymphocytes recognize the immediate-early transactivator ZTA of Epstein-Barr virus,”J. Virol., 69(8):4872-4879, 1995.
Boyson et al., The MHC class I genes of the rhesus monkey,J. Immunol. 156:4656-4665, 1996.
Braciale et al., “Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes,”Immunol. Rev., 98:95-114, 1987.
Carmichael et al., “Quantitative analysis of the human immunodeficiency virus Type I (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease,”J. Exp. Med., 177:249-256, 1993.
Casement et al., “Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type I,”Virology, 211(1):261-67 1995.
Chopra et al., “Cloning and expression of putative cytotonic enterotoxin-encoding genes fromAeromonas hydrophila,” Gene139:87-91, 1994.
Chopra et al., Molecular and biochemical characterization of a heat-labile cytotonic enterotoxin fromAeromonas hydrophila, Microbial Path. 21:357-377, 1996.
Ciernik et al., “Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes,”J. Immunol., 156:2369-2375, 1996.
Clerget-Raslain et al., “Specificity of anti-peptide antibodies elicited against synthetic peptides mimicking conserved regions of HIV1 envelope glycoprotein,”Res. Virol., 142:423-438, 1991.
Dadaglio et al., “Epitope recognition of conserved HIV envelope sequences by human cytotoxic T lymphocytes,”J. Immunol., 147:2302-2309, 1991.
Dai et al., “Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+A24-restricted cytotoxic T lymphocytes,”J. Virol., 66:3151-3154, 1992.
De Rossi et al., “Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism,”Virology, 184:187-196, 1991.
Gorse et al., “Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein,”Vaccine, 13(13):1170-1179, 1995.
Goulder et al., “Novel, cross-restricted, conserved and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type I infection,”AIDS Res. Hum. Retroviruses, 12(18):1691-1698, 1996.
Gussow et al., “Isolation, expression and the primary structure ofHLA-Cw1andHLA-Cw2genes: evolutionary aspects,”Immunogenetics, 25:313-322, 1987.
Imaoka et al., “Nasal immunization of nonhuman primates with simian immunodeficency virus p. 55gagand cholera toxin adjuvant induces Th1/Th2 help for virus specific immune responses in reproductive tissues,”J. Immunol., 161:5952-5958, 1998.
Ishioka et al., “Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes,”J. Immunol., 162:3915-3925, 1999.
Jassoy et al., “Detection of a vigourous HIV-1-specific cytotoxin T lymphocyte response in cerebrospinal fluid from infected persons with AIDS dementia complex,”J. Immunol., 149:3113-3119, 1992.
Johnson et al., “Identification of overlapping HLA class I-restricted cytotoxic epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation,”J. Exp. Med., 175:961-971, 1992.
Johnson et al., “Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone,”J. Virol., 67(1):438-445, 1993.
Kast et al., “Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide,”Proc. Nat'l Acad. Sci. USA, 88:2283, 1991.
Keusch et al., “Classification of enterotoxins on the basis of activity in cell culture,”J. Infect. Dis. 131(1):58-63, 1973.
Klein et al., “Kinetics of gag-specific cytotoxic T-lymphocyte responses during the clinical course of

Affiliated with

Also associated with

Rating

HIV-specific T-cell induction does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HIV-specific T-cell induction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV-specific T-cell induction will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3862719